Indolent B-cell non-Hodgkin lymphoma
MONDO:0017594Also known as: indolent B-cell NHL, B cell lymphoma, indolent, indolent B cell lymphoma
3037 clinical trials for this condition and its sub-types, 69 tagged with Indolent B-cell non-Hodgkin lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Indolent B-cell non-Hodgkin lymphoma
-
Follicular lymphoma 590 trials
-
B-cell chronic lymphocytic leukemia 509 trials · 538 incl. sub-types
2 sub-types
- Chronic lymphocytic leukemia/small lymphocytic lymphoma 108 trials · 109 incl. sub-types Sub-types →
- Hairy cell leukemia 40 trials Sub-types →
-
Marginal zone lymphoma 213 trials · 232 incl. sub-types
4 sub-types
- MALT lymphoma 30 trials · 31 incl. sub-types Sub-types →
- Splenic marginal zone lymphoma 20 trials
- Nodal marginal zone B-cell lymphoma 16 trials
- Splenic diffuse red pulp small B-cell lymphoma 0 trials
-
Waldenstrom macroglobulinemia 136 trials
2 sub-types
- Macroglobulinemia, Waldenstrom, 1 2 trials
- Macroglobulinemia, Waldenstrom, 2 0 trials
-
Indolent primary cutaneous B-cell lymphoma 1 trial · 2 incl. sub-types
2 sub-types
Most studied deeper sub-types
-
Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
Cure Not yet recruitingThis phase 1 trial is testing an experimental therapy called CD19/CD20 dual-target in vivo CAR-T for people with relapsed or refractory B-cell malignancies—blood cancers that have not responded to standard treatments. The approach uses a lentiviral product to engineer a patient's…
Phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Cure
Last updated Aug 15, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat lymphoma patients
Disease control Not yet recruitingThis Phase 2 trial tests lisaftoclax, an oral drug that blocks a protein helping cancer cells survive. It enrolls 75 adults with certain slow-growing lymphomas (CLL, WM, or MZL) who either cannot take standard BTK inhibitors due to health issues or have stopped them due to side e…
Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New cocktail aims to tame Slow-Growing blood cancers
Disease control Not yet recruitingThis Phase II trial will test a combination of pomalidomide, an anti-CD20 antibody, and prednisone as a first treatment for people with indolent (slow-growing) B-cell lymphomas. About 30 adults who have not had prior therapy will receive six cycles of the combo, followed by two y…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New immune combo aims to fight lymphoma without chemo
Disease control Not yet recruitingThis study tests a new drug combination for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The treatment uses three immune-based drugs (CD19 t-haNK, NAI, and rituximab) without chemotherapy. About 20 adults …
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo therapy targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior therapy. The first part finds the safest dose, and the second part checks how well the combina…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC